Annual financial impact of well-differentiated thyroid cancer care in the United States
Article first published online: 30 JAN 2014
© 2014 American Cancer Society
Volume 120, Issue 9, pages 1345–1352, 1 May 2014
How to Cite
Lubitz, C. C., Kong, C. Y., McMahon, P. M., Daniels, G. H., Chen, Y., Economopoulos, K. P., Gazelle, G. S. and Weinstein, M. C. (2014), Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer, 120: 1345–1352. doi: 10.1002/cncr.28562
- Issue published online: 22 APR 2014
- Article first published online: 30 JAN 2014
- Manuscript Accepted: 6 DEC 2013
- Manuscript Revised: 13 NOV 2013
- Manuscript Received: 13 SEP 2013
- cost analysis;
- thyroid cancer;
- economic analysis;
- cost of cancer care
Well-differentiated thyroid cancer (WDTC) is a prevalent disease, which is increasing in incidence faster than any other cancer. Substantial direct medical care costs are related to the diagnosis and treatment of newly diagnosed patients as well as the ongoing surveillance of patients who have a long life expectancy. Prior analyses of the aggregate health care costs attributable to WDTC in the United States have not been reported.
A stacked cohort cost analysis was performed on the US population from 1985 to 2013 to estimate the number of WDTC survivors in 2013. Incidence rates, and cancer-specific and overall survival were based on Surveillance, Epidemiology, and End Results (SEER) data. Current and projected direct medical care costs attributable to the care of patients with WDTC were then estimated. Health care–related costs and event probabilities were based on Medicare reimbursement schedules and the literature.
Estimated overall societal cost of WDTC care in 2013 for all US patients diagnosed after 1985 is $1.6 billion. Diagnosis, surgery, and adjuvant therapy for newly diagnosed patients (41%) constitutes the greatest proportion of costs, followed by surveillance of survivors (37%), and nonoperative death costs attributable to thyroid cancer care (22%). Projected 2030 costs (in 2013 US dollars) based on current incidence trends exceed $3.5 billion.
Health care costs of WDTC are substantial. Unlike other cancers, the majority of the cost is incurred in the initial and continuing phases of care. With the projected increasing incidence, population, and survival trends, costs will continue to escalate. Cancer 2014;120:1345–1352. © 2014 American Cancer Society.